Browsing Tag
Citius Pharmaceuticals
7 posts
Citius Oncology (CTOR) balances LYMPHIR launch momentum with cash runway pressure after Q2 loss
Citius Oncology has LYMPHIR revenue, but cash runway only reaches November 2026. Investors now face launch proof versus dilution risk.
Citius Oncology (CTOR) stock in focus as $36.5m financing targets LYMPHIR commercialization
Citius Oncology has capital and an approved CTCL drug. The harder question is whether LYMPHIR can turn niche oncology promise into revenue.
What the LYMPHIR–pembrolizumab combination signals for the future of immunotherapy resistance (NASDAQ: CTOR)
Citius Oncology reports LYMPHIR immunotherapy data in gynecologic cancers. Discover what the trial signals for the future of cancer immunotherapy.
Citius Oncology bets on AI-powered sales strategy to fast-track LYMPHIR cancer drug launch
Citius Oncology launches an AI-powered platform to boost LYMPHIR’s commercial debut in CTCL, reshaping oncology sales strategies with precision targeting.
Dr. Reddy’s Labs signs deal worth up to $150m to sell E7777 rights to Citius
Dr. Reddy’s Laboratories (Dr. Reddy’s Labs) has agreed to divest its rights to E7777, an engineered IL-2-diphtheria toxin…
Citius seeks FDA nod for evaluating stem cell therapy for ARDS in COVID-19
Citius Pharmaceuticals has made a Pre-IND submission to the US Food and Drug Administration for a novel stem…
Citius Pharmaceuticals expands scientific advisory board to enhance focus on infectious disease treatments
Citius Pharmaceuticals, a specialty pharmaceutical company based in New Jersey, has announced the addition of Dr. Lawrence Mermel…